Snapshot: How the NCD for Home Ventilation Is Playing Out for DMEs today

What the Medicare coverage rule means for DME providers, patients, and the future of respiratory RCM

In June 2025, CMS released a landmark policy that reshaped how Medicare covers home-based respiratory therapy. The National Coverage Determination for Noninvasive Positive Pressure Ventilation in the Home for the Treatment of Chronic Respiratory Failure Consequent to COPD commonly called the NIPPV NCD took effect for claims on October 22, 2025. For the first time, Medicare established uniform national coverage criteria for both respiratory assist devices (RADs) and home mechanical ventilators (HMVs) for patients with COPD. What was previously left to the discretion of individual Medicare Administrative Contractors (MACs) resulting in wildly inconsistent access across regions is now governed by a single national standard.

More than seven months into implementation, the picture emerging from the market is complicated. Access has expanded in some ways. In others, the rule's compliance requirements are putting life-sustaining equipment at risk for patients whose physicians believe it remains medically necessary. Here is where things stand.

What Changed When the NCD Took Effect

Before the NCD, Medicare coverage for RADs and HMVs was fragmented. Each MAC region could set its own local coverage determination (LCD), creating a patchwork of eligibility standards that left providers and patients in different parts of the country operating under completely different rules. The new NCD supersedes all prior LCDs for these devices in the context of COPD, and complicated revenue cycle management for the DME industry.

As VGM & Associates noted in its provider guidance, the payment categories themselves are unchanged; the RAD remains a capped rental for 13 months. But the documentation and compliance obligations are substantially new, and the operational challenge of managing them at scale is real.

How the Rule Is Playing Out for Providers

Providers who were already running structured respiratory programs have fared better than those who weren't. The adjustment has been real, but manageable for organizations with the right infrastructure.

"The biggest adjustment was dedicating time to refresh training, update our internal checklists, and make sure staff and ordering physicians were fully aligned with the new CMS requirements," said Katelyn Fincher, respiratory care manager at M.R.S. at Home, as reported by HME News. "Our foundation was already solid, so these were more refinements than big changes."

For providers without that foundation, the new compliance monitoring obligations have been a harder lift. And in rural areas, the ABG testing requirement is emerging as a genuine access barrier. Outpatient ABG testing is simply not readily available in many markets.

As Homecare Magazine noted in its August 2025 coverage, this NCD marks a shift for HME providers from equipment delivery to compliance-driven care coordination. How providers respond will determine whether they thrive or fall behind.

What Viemed's Results Tell Us About the Market

Viemed Healthcare, the largest specialized home ventilator provider in the US, is a useful barometer. As reported by HME News, the company is hitting what CEO Casey Hoyt called an inflection point: stronger compliance among active patients, accelerating new referrals, and patient turnover that is higher than before the NCD took effect.

The numbers tell a nuanced story:

• Active patient compliance improved by nearly 20% since the NCD took effect in October 2025
• Q1 2026 revenues reached $75.4 million up 28% year-over-year
• March 2026 recorded 759 new ventilator setups, compared to 692 in March 2025 a record month
• The company holds a 100% ALJ success rate on Medicare Advantage denials, validating the clinical appropriateness of the patients it serves
• Patient turnover is higher, as some patients fail to meet the new compliance thresholds

‍

"While the compliance policy does not necessarily threaten our financial success as a company, it absolutely impacts the patients who are benefiting from care," Hoyt said.

Perhaps the most notable signal: patients who were previously denied under more subjective Medicare Advantage criteria are now qualifying under the standardized NCD criteria. The national standard, for all its challenges, is providing a clearer and more defensible pathway to coverage than the prior patchwork of MAC policies.

The Compliance Burden Is Now a DME Operations Problem

This is where the NCD intersects directly with DME revenue cycle management. The new rule doesn't just change who qualifies for equipment it changes what providers have to do every month to keep that equipment covered.

Managing compliance under the NCD requires providers to:

• Track daily usage data from patient devices and identify non-compliance before rental claims are submitted
• Coordinate ABG testing at initial eligibility and within six months of therapy start
• Ensure physician re-evaluations occur on schedule and are properly documented
• Monitor for continued-use criteria failures and initiate patient outreach before coverage lapses
• Manage documentation across RAD and HMV categories with different criteria thresholds

‍

This is a documentation-intensive, time-sensitive workflow. Done manually, it is the same kind of bottleneck that has always plagued DME RCM except now the stakes are higher, because a missed re-evaluation or a month of underdocumented usage can result in a patient losing access to life-sustaining therapy.

AI-powered DME automation, the kind that monitors compliance data, flags documentation gaps before claims are submitted, and creates pre-flight visibility into what is likely to fail, is no longer a nice-to-have for respiratory providers. It is how providers protect both their patients and their revenue cycle under the new NCD.

What Comes Next

The industry is watching for CMS to issue clearer guidance on continuing-use criteria and the adherence threshold for COPD patients the specific clarifications AAHomecare and its coalition requested in April 2026. Without that guidance, audit risk remains elevated and providers are essentially operating on informal interpretations.

Longer term, the NCD is likely to reshape the respiratory provider landscape. As Viemed's management has noted, increased compliance and documentation requirements tend to favor larger, well-capitalized providers that have the technology and infrastructure to manage regulatory complexity. Smaller providers that cannot build or buy that infrastructure may struggle to remain competitive in this category.

The providers who come out ahead will be the ones who treat this not as a compliance burden, but as an operations problem one that can be solved with the right systems, the right documentation discipline, and the right automation layer between their billing team and their patients' devices.

Notable Systems Helps Respiratory Providers Stay Ahead of NCD Requirements

Notable Systems' AI-powered DME automation software is built for exactly this kind of compliance-driven environment. Intake Manager and Claims Manager work together to catch documentation gaps before claims are submitted giving respiratory providers pre-flight visibility into coverage issues that would otherwise surface as denials weeks later.

If your team is navigating the new NIPPV NCD requirements and needs a more scalable approach to compliance documentation and prior authorization, we'd be glad to walk you through how we approach it.

‍

Sources

HME News: CMS releases final NCD for non-invasive ventilation

HME News: Preparedness varies as ventilator NCD requirement takes hold

HME News: Viemed juggles diversified portfolio

VGM & Associates: A Quick Guide to the New NCD for Non-Invasive Positive Pressure Ventilation

VGM & Associates: Navigating the New CMS Landscape with the HMV and RAD Decision Memo for COPD

Homecare Magazine: CMS Releases Final NCD on Noninvasive Positive Pressure Ventilation

Homecare Magazine: Understanding the New NCD for Noninvasive Ventilation

AAHomecare Stakeholder Letter to CMS April 2026

‍